目的 觀察疏風解毒膠囊聯(lián)合消銀顆粒治療尋常型銀屑?。ㄑ獰嶙C）的臨床療效。方法 選取2013年6月—2015年6月來周口市中心醫(yī)院皮膚科就診的尋常型銀屑病患者98例，按就診時間分為對照組（46例）和治療組（52例）。對照組口服消銀顆粒，1袋/次，3次/d。治療組在對照組治療基礎上口服疏風解毒膠囊，4粒/次，3次/d。兩組均連續(xù)治療2個月。觀察兩組的臨床療效，比較兩組治療前后腫瘤壞死因子α（TNF-α）、白細胞介素4（IL-4）、白細胞介素17（IL-17）、銀屑病皮損面積嚴重指數(shù)（PASI）評分的變化情況。結(jié)果 治療后，對照組和治療組的總有效率分別為67.4%、84.6%，兩組比較差異具有統(tǒng)計學意義（P < 0.05）。治療后，兩組患者TNF-α、IL-4、IL-17、PASI評分均較治療前顯著降低，同組治療前后差異有統(tǒng)計學意義（P < 0.05）；治療后，治療組TNF-α、IL-4、IL-17、PASI評分低于對照組，兩組比較差異具有統(tǒng)計學意義（P < 0.05）。結(jié)論 疏風解毒膠囊聯(lián)合消銀顆粒治療尋常型銀屑?。ㄑ獰嶙C）具有較好的臨床療效，可降低PASI評分和相關因子水平，具有一定的臨床推廣應用價值。

Objective To observe the efficacy of Shufeng Jiedu Capsules compared with Xiaoyin Granules in treatment of psoriasis vulgaris (blood-heat syndrome). Methods Patients (98 cases) with psoriasis vulgaris in Zhoukou Central Hospital from June 2013 to June 2015 were divided into control (46 cases) and treatment (52 cases) groups according to the clinic time. Patients in the control group were po administered with Xiaoyin Granules, 1 bag/time, three times daily. Patients in the treatment group were po administered with Shufeng Jiedu Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for two months. After treatment, the clinical efficacy was evaluated, and the changes of TNF-α, IL-4, IL-17, and PASI scores before and after treatment in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 67.4% and 84.6%, respectively, and there was difference between two groups (P < 0.05). After treatment, TNF-α, IL-4, IL-17, and PASI scores significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, TNF-α, IL-4, IL-17, and PASI scores in the treatment group were lower than those in the control group, and there was difference between two groups (P < 0.05). Conclusions Shufeng Jiedu Capsules compared with Xiaoyin Granules has significant clinical effect in treatment of psoriasis vulgaris (blood-heat syndrome), and can reduce the PASI scores and related factors, which has a certain clinical application value.